OTCMKTS:CYTR LadRx (CYTR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About LadRx Stock (OTCMKTS:CYTR) 30 days 90 days 365 days Advanced Chart Get LadRx alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume4,000 shsAverage Volume99,706 shsMarket Capitalization$4.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California. Read More Receive CYTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTR Stock News HeadlinesLord Abbett Developing Growth R3 (LADRX)October 17, 2024 | ca.finance.yahoo.comLord Abbett Developing Growth R3September 18, 2024 | morningstar.comM$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 5 at 2:00 AM | Brownstone Research (Ad)Lord Abbett Developing Growth Fund;R3September 17, 2024 | wsj.comLadRx Corporation (LADX) Latest Stock News & Headlines - Yahoo FinanceAugust 25, 2024 | finance.yahoo.comNasdaq Korea Consumer Staples Index (NQKR45:IND) Stock Price, Quote, News & Analysis - Seeking AlphaJuly 19, 2024 | seekingalpha.comLadRx Corporation (LADX)May 17, 2024 | finance.yahoo.comLadRx Corporation (LADX) Stock Historical Prices & Data - Yahoo FinanceAugust 11, 2023 | finance.yahoo.comSee More Headlines CYTR Stock Analysis - Frequently Asked Questions How were LadRx's earnings last quarter? LadRx Co. (OTCMKTS:CYTR) issued its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. When did LadRx's stock split? LadRx's stock reverse split on Wednesday, November 1st 2017.The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. How do I buy shares of LadRx? Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LadRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that LadRx investors own include Biopharmx (BPMX), SELLAS Life Sciences Group (SLS), Rexahn Pharmaceuticals (REXN), Arrowhead Pharmaceuticals (ARWR), Aurinia Pharmaceuticals (AUPH), Idera Pharmaceuticals (IDRA) and Protalix BioTherapeutics (PLX). Company Calendar Last Earnings8/09/2019Today7/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CYTR CIK799698 Webwww.cytrx.com Phone(310) 826-5648Fax310-826-6139Employees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.70 million Net MarginsN/A Pretax MarginN/A Return on Equity-67.61% Return on Assets-45.39% Debt Debt-to-Equity RatioN/A Current Ratio5.94 Quick Ratio5.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares45,037,000Free Float33,834,000Market Cap$4.14 million OptionableNot Optionable Beta1.96 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:CYTR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LadRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share LadRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.